Faculty Collaboration Database

Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008 Jul;48(7):1087-95 PMID: 18687081

Pubmed ID

18687081

DOI

10.1111/j.1526-4610.2008.01185.x

Abstract

The term chronic daily headache refers to a heterogeneous group of headache disorders characterized by a frequency of headaches on > or = 15 days per month. Chronic migraine is a subtype of chronic daily headache. The prevalence of chronic migraine is approximately 1%. Baseline attack frequency and acute medication overuse have been identified as potential risk factors for the progression of migraine from an episodic disorder to a chronic condition. There is an unmet patient need for effective and safe treatments for patients with chronic migraine, but data from rigorous controlled trials are limited. Previous studies have demonstrated that topiramate is an effective and safe preventive treatment for episodic migraine. In addition, pilot studies have suggested the utility of topiramate for the prevention of chronic migraine. Two randomized, double-blind, placebo-controlled, multicenter trials investigating the efficacy and safety of topiramate in the treatment of patients with chronic migraine have recently been completed. This review presents comparative data from these 2 clinical trials, which suggest that topiramate at a dose of 100 mg daily is effective and generally well tolerated in chronic migraine.

Author List

Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, Freitag F, Schwalen S, Ascher S, Morein J, Greenberg S, Biondi D, Hulihan J

Author

Frederick G. Freitag DO Associate Professor in the Neurology department at Medical College of Wisconsin

Scopus

2-s2.0-46749137929   28 Citations

MESH terms used to index this publication - Major topics in bold

Chronic Disease
Fructose
Headache Disorders
Humans
Migraine Disorders
Randomized Controlled Trials as Topic
Risk Factors
Treatment Outcome